Andrew John Armstrong MD, ScM, FACP

Dr. Andrew John Armstrong is a Professor of Medicine, Surgery, Pharmacology, and Cancer Biology and Director of Research for the Duke Cancer Institute’s Center for Prostate and Urologic Cancer. He is a medical oncologist and internationally recognized expert in experimental therapeutics and biomarker development in genitourinary cancers, particularly in prostate cancer. He trained at Duke as a biomedical engineer and received his medical degree at the University of Virginia. He completed medicine residency training at the University of Pennsylvania, and fellowship and public health clinical investigation training at Johns Hopkins and the Bloomberg School of Public Health.

Dr. Armstrong has developed a number of experimental agents in prostate and renal cell cancer, including AR inhibitors, immunotherapies, mTOR/PI3K inhibitors, and anti-angiogenic agents, and he is heavily involved in the leadership of multiple ongoing phases 1-4 treatment and biomarker trials in men with advanced prostate cancer, including serving as correlative science chair within the NCI ALLIANCE Cooperative Group in the GU Committee. He has authored over 160 peer-reviewed publications, as well as numerous chapters, reviews, and abstracts. He leads a team of over 50 research nurses, coordinators, data managers, regulatory specialists, scientists, and investigators dedicated to discovering science in GU cancers in the laboratory and treatment science in the clinic.